Captopril CF

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Captopril CF

Property Description
Active ingredient Captopril
Form Oral tablet
Pharmacological class Angiotensin-Converting Enzyme (ACE) inhibitor
Common use Management of high blood pressure (Antihypertensive agent)
Origin Synthetic compound

What Type of Medicine is Captopril CF?

Captopril is a synthetic compound classified as an Angiotensin-Converting Enzyme (ACE) inhibitor, which places it within a core pharmacological class of antihypertensive agents. As an ACE inhibitor, its primary function is to influence the body’s systemic regulation of blood pressure and vascular tone. This medicine, which is clinically recognized for its rapid onset of action compared to certain other agents in its class, is designed for systemic action to manage and support the cardiovascular system. It is recognized as an essential medicine, underscoring its therapeutic importance globally.


Composition, Form, and General Purpose

The active ingredient in Captopril CF is Captopril, which is delivered as a single-ingredient product in an oral tablet for oral administration. The Captopril compound is structurally notable for containing a sulfhydryl group, a feature that is essential to its precise therapeutic effect of blocking the ACE enzyme. Captopril is used to reduce high blood pressure and lessen the workload on the heart. This general action improves the functional efficiency of the cardiovascular system by decreasing the overall strain. The final oral formulation consists of the active substance combined with a solid oral vehicle, ensuring stability and convenient delivery to adults.

Regulatory References

  1. Captopril: Mechanism of Action (ACE Inhibitor)
  2. ATC Code C09AA01 (Captopril)
  3. Captopril: Chemical Structure and Thiol Moiety
  4. Captopril European Commission Registration

What side effects are possible with Captopril CF?

Possible Side Effects and Safety Information

The safety profile of Captopril CF is defined by adverse reactions classified according to official regulatory frequencies and grouped by affected organ systems. This medicine is an Angiotensin-Converting Enzyme (ACE) inhibitor, and its safety information is derived from government-approved prescribing documents.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized by the likelihood of their occurrence, consistent with regulatory guidelines:

  • Common (1% to 10%): Include taste impairment, dizziness, cough, and rash. These effects are generally associated with the initial phase of treatment.
  • Uncommon (0.1% to 1%): Includes angioedema, tachycardia (fast heartbeat), and fatigue.
  • Rare and Very Rare (less frequent): These categories document less common events such as stomatitis (mouth sores), headache, neutropenia (low white blood cell count), and hyperkalemia (high potassium level).

Documented Serious Safety Concerns

Specific serious adverse reactions are highlighted in regulatory labeling: Angioedema (swelling of the face, tongue, or throat) is a serious concern that may occur, particularly early in therapy. Severe blood disorders, such as neutropenia and agranulocytosis, are very rare but documented risks, especially in patients with co-existing renal impairment or collagen vascular disease. Acute renal failure and severe hypotension (low blood pressure) are also documented.

Population-Specific Safety Considerations

The use of Captopril CF is constrained by specific safety considerations for certain patient groups. It is contraindicated for use during the second and third trimesters of pregnancy due to the risk of fetal injury or death. Patients with pre-existing renal impairment have an increased risk of specific adverse reactions, requiring particular attention as documented in official safety literature.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Captopril CF is primarily defined by a severe extension of the medicine’s core pharmacological effect, leading to profound hemodynamic instability. Documented clinical manifestations include severe hypotension, a state of shock, lethargy, and bradycardia (abnormally slow heart rate). Life-threatening outcomes that may result from gross overdosage are renal failure and the potential for a fatal outcome associated with severe complications like airway obstruction due to angioedema.

In any suspected overdose situation, official guidance mandates seeking immediate emergency medical attention. Emergency services must be called immediately if the affected person collapses, has a seizure, cannot be awakened, or experiences trouble breathing. Contacting a Poison Control helpline is also required.

The officially described treatment for Captopril overdose is supportive and symptomatic, as no specific antidote is documented in the labeling. Management includes placing the patient in a supine position and administering intravenous hydration with physiological saline to address severe hypotension. Monitoring requirements include observation periods of at least four hours for asymptomatic patients and admission for a minimum of 24 hours for symptomatic individuals, with continuous assessment of blood pressure, electrolytes, and serum creatinine.

Therapeutic Uses of Captopril CF

What Captopril CF Treats: Main Uses and Benefits

Captopril CF is commonly used to help manage symptoms and risks across four key areas: chronic high blood pressure (hypertension), heart failure, support following a recent heart attack, and kidney health maintenance, particularly for individuals with diabetes. The primary therapeutic benefits include easing the overall symptom load, supporting functional stability, and contributing to improved comfort.

This medication is applied in clinical settings where the heart's function may be compromised, helping to manage distressing symptoms such as shortness of breath, persistent fatigue, and swelling in the limbs associated with systemic imbalance. It provides supportive benefit that helps ease the overall burden of these symptoms, contributing to improved day-to-day comfort and supporting more manageable physical activity. Captopril is commonly used to treat heart failure and is applied to provide additional support during the heart recovery period.

“The supportive relief from Captopril CF helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Fluid Build-up

This use is commonly applied for managing the long-term strain on the cardiovascular system, providing supportive relief. It is applied in addressing conditions where functional stability becomes affected and assists with maintaining functional stability in conditions linked to organ-specific functional stress. This is relevant for patients with diabetes and high blood pressure, and it may support general well-being during symptomatic phases by assisting with the physiological needs of the heart.

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility for Captopril CF, containing the active ingredient Captopril, is defined by strict regulatory criteria across several population groups. Use is allowed for the general adult population when treating standard labeled indications.

Category Regulatory Status
Absolute Contraindication Patients with a history of angioedema related to any previous ACE inhibitor or those with hereditary/idiopathic angioedema.
Pregnancy Contraindicated in the second and third trimesters. Use is not recommended in the first trimester.
Drug-Related Prohibition Contraindicated with concomitant use of aliskiren in patients with Type 2 Diabetes Mellitus or moderate-to-severe renal impairment. Also prohibited with neprilysin inhibitors.
Pediatric Use Not established or not recommended for use in newborns and infants. Restricted use in older children for specific conditions.
Organ Restriction Conditional use required for severe renal impairment (mandatory dose reduction) and use with caution for hepatic impairment.

The official profile uses clear classifications such as Contraindicated and Not Recommended to establish absolute boundaries for those who must not use the medicine (e.g., specific hypersensitivities, later-stage pregnancy) and to mandate special consideration for patients with organ dysfunction or specific comorbidities.

What should I know about interactions with other medicines?

Captopril CF has officially documented interaction patterns with certain medicinal products and substances, which are outlined in government regulatory information.

Formal Contraindications and Timing Rules

Co-administration of Captopril with Sacubitril/Valsartan is formally contraindicated, as this combination significantly increases the documented risk of angioedema. A mandatory separation period requires Captopril not to be initiated earlier than 36 hours after the last dose of Sacubitril/Valsartan. The combination with Aliskiren is contraindicated specifically for patients with pre-existing diabetes mellitus or documented renal impairment (GFR less than 60 mL/min/1.73 m^2).

Interactions Affecting Electrolytes and Renal Function

The combination with Potassium-sparing diuretics (such as Spironolactone) and Potassium supplements carries a high regulatory documented risk of hyperkalemia (elevated serum potassium concentrations). NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) may officially attenuate the blood pressure-lowering effect and increase the risk of reduced kidney function. Co-administration of Immunosuppressive agents (like Allopurinol) heightens the risk of neutropenia, especially in individuals with impaired renal function. The use of Lithium can increase serum lithium concentrations and the risk of toxicity. mTOR inhibitors are also documented to increase the risk of angioedema.

Exposure Modification and Other Agents

Interactions affecting exposure are noted: Antacids (specifically Aluminum Hydroxide) may officially decrease Captopril absorption. Certain CYP2D6 enzyme inhibitors (e.g., Mavorixafor, Abiraterone) are documented to increase Captopril plasma exposure. Furthermore, official labeling notes that food intake reduces the oral absorption of Captopril, and alcohol consumption may lead to additive hypotensive effects.

Mechanism of Action

The primary mechanism involves Captopril acting as a competitive inhibitor that targets the Angiotensin-Converting Enzyme (ACE). Its molecular structure contains a sulfhydryl group that binds strongly to the zinc ion site on ACE, structurally blocking the enzyme’s ability to function. This molecular interference suppresses the body's main pathway for converting Angiotensin I into the vasoconstrictor, Angiotensin II.

Inhibiting ACE creates a dual regulatory effect on systemic vascular tone. By reducing Angiotensin II synthesis, it removes a key signal for vasoconstriction. Simultaneously, because ACE is the same enzyme that breaks down Bradykinin (a natural vasodilating peptide), its inhibition leads to increased Bradykinin levels. This two-pronged action of suppressing a constrictor and potentiating a dilator contributes to a systemic reduction in peripheral arterial resistance and a reduction in cardiac workload.

The systemic reduction of Angiotensin II also leads to a secondary, hormonal consequence: decreased secretion of Aldosterone. This shift in the renal hormone axis influences fluid balance by promoting the excretion of sodium and water (natriuresis), contributing to a decreased circulating volume. These integrated physiological adjustments—vasodilation, reduced Preload and Afterload, and volume modulation—collectively result in the drug's physiological effect profile.

Dosage and Administration Information

Standard protocols for Captopril provide specific instructions to ensure consistent use across various clinical settings. These instructions define the route, timing, and dosage schedule.

Administration Scope

Feature Guideline
Route of Administration Oral administration as a tablet.
Timing in relation to meals Must be taken on an empty stomach, specifically one hour before consuming food.
Frequency and Schedule Dosing is typically administered in divided doses, two or three times daily (BID or TID).
Special Procedural Conditions The tablet form is often scored, facilitating division to achieve lower initial doses. Treatment initiation in high-risk patient groups should occur under close medical supervision.

Dosage Initiation and Adjustment Protocol

The starting dose for Captopril is typically low, such as 6.25 mg to 25 mg depending on the specific indication. The standard protocol involves a gradual dose titration, with increases typically occurring at intervals of one to two weeks until the desired maintenance dose is reached. The maximum daily dose generally does not exceed 450 mg/day.

Population-Specific Adjustments: Patients with renal impairment or older adults typically require a reduced initial dose and a slower titration schedule due to noted differences in drug clearance.

Missed-Dose Rule: If a dose is missed, it should be taken immediately unless it is almost time for the next scheduled dose, in which case the missed dose must be skipped. A double dose must never be taken to compensate.

Recent Clinical Evidence

Captopril CF: Recent Clinical Evidence

This section provides an overview of the official research structure used to evaluate Captopril, including the types of studies that have been conducted and the questions they addressed, without offering any clinical advice or interpretation.


Evidence for Core Indications

Captopril's evaluation for Chronic High Blood Pressure relies on Randomized Controlled Trials (RCTs) that measured systolic and diastolic blood pressure over defined intervals, as well as rates of major cardiovascular events. For Heart Failure, large-scale, placebo-controlled trials monitored survival rates, the frequency of hospitalization, and changes in functional capacity. Studies for Post-Recent Heart Attack focused on monitoring survival and the incidence of subsequent cardiac events, including the study of ventricular remodeling. Research for Kidney Health Maintenance in diabetic patients used long-term RCTs to monitor the rate of decline in Glomerular Filtration Rate (GFR) and the amount of protein in the urine. In all cases, data show patterns related to these outcomes in the observed populations.

Long-Term Research and Uncertainty

While the major clinical trials often involved follow-up durations extending two to five years to monitor severe events, long-term effects are not fully established for all patient populations over a lifetime. Captopril was evaluated in studies that included older adults and those with diabetes (comorbidity-defined groups); however, data for groups such as pediatric populations remain insufficient, and sample sizes were often modest. Research highlights that comparative evidence against the newest medicines is constantly evolving, and certainty remains low regarding its application in certain contemporary conditions, such as specific forms of heart failure where the pumping function is preserved.

Key Studies & References

  1. Captopril - StatPearls (Review of Indications: Hypertension, Heart Failure, Post-MI, Diabetic Nephropathy)

Frequently Asked Questions (FAQ)

Common questions about Captopril CF (FAQ)

Q: Is Captopril CF the same as Captopril?

The active ingredient in Captopril CF is Captopril. Captopril is also available as a generic medicine in oral tablet form. In the United States, the original brand-name product that contained Captopril is no longer on the market.


Q: How quickly does Captopril CF start working?

Captopril is rapidly absorbed after being taken orally. Regulatory documents indicate that maximum concentrations in the blood are usually reached in about one hour. The full blood pressure-lowering effect is typically seen about 60 to 90 minutes after taking a dose.


Q: What happens if I forget to take Captopril CF?

Official guidelines provide a rule for missed doses. If a dose is forgotten, it should be taken immediately unless it is almost time for the next scheduled dose. If that is the case, the missed dose must be skipped. A double dose must not be taken to compensate for a missed dose, as stated in official product information.


Q: Is it common to feel dizzy when taking Captopril CF?

Dizziness is documented in official product information as a common side effect. It is reported in 1% to 10% of patients and is often associated with the initial phase of treatment.


Q: Can Captopril CF cause a dry cough?

Cough is documented as a common side effect of Captopril CF, reported in up to 10% of patients. The cough associated with ACE inhibitors is often described as non-productive or dry. Official documents explain this effect is related to the drug's mechanism of impeding the breakdown of a natural substance called bradykinin.


Q: How long does the effect of Captopril CF last after taking a dose?

The time the unchanged drug remains in the body is relatively short, with its half-life documented as less than two hours. The duration of the blood pressure reduction effect is generally considered to be dose-related.


Q: Are there any foods or drinks I should limit while on Captopril CF?

Regulatory documents strictly state that food intake reduces the oral absorption of Captopril. Official labeling indicates that the consumption of alcohol may contribute to additive low blood pressure effects. Additionally, the use of potassium supplements or certain salt substitutes carries a high documented risk of elevated potassium levels (hyperkalemia).


Q: Can Captopril CF be taken with milk or food?

Regulatory guidelines specify that Captopril is not typically taken with food. Official instructions state Captopril must be taken on an empty stomach, specifically one hour before consuming food, because food intake is documented to reduce the absorption of the medicine.


Q: Can Captopril CF be taken alongside aspirin?

Aspirin is part of a drug category known as NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Official documentation indicates that NSAIDs may reduce the blood pressure-lowering effect of Captopril CF. Co-administration may also be associated with an increased regulatory documented risk of reduced kidney function.


Q: Is Captopril CF a diuretic (water pill)?

Captopril CF is classified as an ACE inhibitor, not a diuretic. However, the drug's action leads to a secondary effect of promoting the excretion of sodium and water (natriuresis) due to hormonal changes. This effect is a contributing factor to its overall cardiovascular function.


Q: Is Captopril CF the same category of drug as Lisinopril?

Yes, Captopril CF and Lisinopril are both classified within the same pharmacological class. They are both Angiotensin-Converting Enzyme (ACE) inhibitors.


Q: How is Captopril CF different from other ACE inhibitors?

Captopril is structurally distinct among some other ACE inhibitors due to its chemical makeup, which contains a sulfhydryl group. It is also clinically recognized for having a rapid onset of action compared to certain other agents in its class.

--IS there a generic version of Captopril CF available?

The active ingredient, Captopril, is widely available as a generic medicine in oral tablet form. The original brand-name product that contained Captopril is no longer marketed.


Q: Does Captopril CF lose its effect over time?

Regulatory studies examining long-term use in patients with heart failure showed no evidence of tolerance to the beneficial effects on exercise time over a period of 12 weeks. Open studies extending up to 18 months also indicate that the benefit is generally maintained over the course of therapy.


Q: What does official evidence say about Captopril CF for high blood pressure?

Official evidence from randomized controlled trials supports the use of Captopril CF for the management of high blood pressure (hypertension). These studies demonstrated a consistent reduction in both systolic and diastolic blood pressure in the observed patient populations.


Q: Where can I find authoritative information about Captopril CF clinical studies?

Authoritative information about Captopril’s clinical studies is available on the websites of government regulatory bodies like the FDA and EMA. You can also find information about the design and results of trials on the NIH-maintained Clinical Trials Registry.


Q: Can Captopril CF be used by people with diabetes?

Yes, Captopril CF has an officially approved use for treating specific kidney disease (diabetic nephropathy) in patients with type 1 insulin-dependent diabetes and retinopathy. However, the interactions section of the label details specific drug combinations that are contraindicated for patients with diabetes.


Q: Is Captopril CF used in children?

Official labeling states that the safety and efficacy of Captopril CF are not established or not recommended for use in children younger than 6 years old. Data supports its restricted use in children aged 6 to 16 years for certain specific conditions.


Q: Why might Captopril CF cause low blood pressure (hypotension)?

The drug's mechanism involves reducing the creation of a hormone called Angiotensin II, which is a key signal for blood vessel tightening (vasoconstriction). This suppression contributes to a systemic widening of blood vessels, which can result in low blood pressure (hypotension).


Q: Will Captopril CF make me feel tired or lethargic?

Fatigue is listed in the official product information as an uncommon side effect, reported in 0.1% to 1% of patients. Excessive tiredness is also noted in patient information materials.


Q: Is a metallic taste in the mouth a reported side effect of Captopril CF?

Yes, an alteration in the sense of taste, known as taste impairment, is a common side effect. Specific descriptions of this effect listed in patient resources include experiencing a salty or metallic taste.


Q: What is the difference between Captopril CF and an ARB drug?

Captopril CF is an ACE inhibitor, which works by blocking the enzyme that produces Angiotensin II. ARB drugs (Angiotensin Receptor Blockers) work differently by blocking the receptors where Angiotensin II acts on blood vessels. They target the same physiological pathway but at different points.


Q: Is it normal to have a small rash when starting Captopril CF?

Rash is documented as a common side effect, reported in up to 10% of patients. Official information notes that this effect is generally associated with the initial phase of treatment.


Q: Can Captopril CF affect results of laboratory tests?

Yes. Official documentation notes that the drug may affect the results of specific laboratory tests. This includes the potential for elevated levels of liver enzymes and hyperkalemia (high potassium level) in blood tests.


Q: Is it possible to develop tolerance to Captopril CF?

Official clinical studies have addressed this question. In studies that monitored patients for up to 12 weeks, regulatory data showed no evidence of tolerance to the drug's main beneficial effects.


Q: Why do some people need to switch from Captopril CF to another medicine?

Regulatory documents describe scenarios for discontinuation, such as the development of a serious side effect like angioedema (swelling), which is listed as an absolute contraindication for use. Switching may also occur if patients experience other unacceptable side effects like a persistent, bothersome cough.


Q: What is the typical expectation for long-term use of Captopril CF?

For chronic conditions, the expectation is generally the maintenance of the drug's therapeutic effects. Official data supports that beneficial effects persist for the duration of therapy, with no indication that tolerance to the main effects develops.


Q: Are there warnings about driving or operating machinery while taking Captopril CF?

Since Captopril CF may cause side effects such as dizziness, fatigue, or low blood pressure, official patient information often suggests caution. It is often recommended not to drive or operate machinery until the patient has a clear understanding of the medicine’s potential effects.

How should Captopril CF be stored and disposed of?

How to Store and Dispose of Captopril CF

Captopril tablets must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with protection from moisture. It is strictly mandated to not freeze the medication. For proper storage, the product must be kept in its original container and the container must remain tightly closed to maintain product stability and integrity.

Child Safety and Disposal

For child safety, the product labeling explicitly instructs to KEEP OUT OF THE REACH OF CHILDREN.

Regarding disposal, patients are required to discard medicine that is outdated or no longer needed. Official regulatory guidance mandates that patients ask a pharmacist or healthcare professional how to properly discard any unused medicine to ensure compliance with local pharmaceutical waste disposal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Captopril CF found in:

A-Z Index: